secwatch.observer — SEC 8-K summary
======================================

Issuer:     ONCOLYTICS BIOTECH INC (ONCY)
CIK:        0001129928
Form:       8-K
Filed at:   2026-09-29T13:34:58+00:00
Accession:  0001129928-26-000059
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Oncolytics' pelareorep data in PNAS show 'cold' liver tumors turned immunotherapy-responsive
--------------------------------------------------------------------------------

- Academic paper 'MicroRNA-driven regulation of immunosuppressive microenvironment in hepatocellular carcinoma' published in Proceedings of the National Academy of Sciences on Sept. 28, 2026.
- Preclinical data show pelareorep reversed immunosuppression in hepatocellular carcinoma, with increases in PD-L1 expression, ICOSL on tumor cells and CD8+ T cell density.
- CMO Thomas Heineman said liver cancer is not an indication Oncolytics intends to pursue now, but the data are aiding business development conversations.
- Paper also notes PD-1/PD-L1 upregulation and Inducible T cell Co-stimulator (ICOS)-ICOSL signaling, conditions cited as necessary for checkpoint inhibitors to work.
- Oncolytics describes pelareorep as an investigational, systemically active immunotherapy that forms tertiary lymphoid structures and expands tumor-infiltrating lymphocytes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000059/0001129928-26-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1129928/000112992826000059/oncy-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001129928-26-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer